home / stock / frln / frln news

FRLN News and Press, Freeline Therapeutics Holdings plc From 11/10/21

Stock Information
Company Name: Freeline Therapeutics Holdings plc
Stock Symbol: FRLN
Market: NASDAQ
Website: freeline.life
Menu
FRLN FRLN Quote FRLN Short FRLN News FRLN Articles FRLN Message Board
Get FRLN Alerts

News, Short Squeeze, Breakout and More Instantly...
FRLN - Freeline to Participate in Stifel 2021 Virtual Healthcare Conference

LONDON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from inherited systemic ...
FRLN - Freeline Reports New Data from Fabry Disease Program, Pipeline and Company Updates, Including Appointment of Pamela Foulds, MD as Chief Medical Officer, and Third Quarter 2021 Financial Results

Lowest dose cohort of MARVEL-1 trial of FLT190 for Fabry disease demonstrates durable α-Gal A expression over two years in the first patient and promising efficacy with near normal α-Gal A levels in the second patient, who remains off enzyme replacement therapy more than 16 ...

FRLN - Freeline Therapeutics to Present FLT180a Data at the 2021 ASH Annual Meeting

LONDON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from inherited systemic ...

FRLN - Freeline Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LONDON, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from inherited systemic ...
FRLN - Freeline Announces Orphan Drug Designations for FLT201 for the Treatment of Gaucher Disease

LONDON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from inherited systemic...

FRLN - Freeline to Participate in Upcoming Investor Conferences in September 2021

LONDON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from inherited systemic...

FRLN - Freeline Appoints Michael J. Parini as Chief Executive Officer and Reports Second Quarter 2021 Financial Results

On track for three programs in the clinic by year end; trial site initiation for FLT180a for Hemophilia B and FLT201 for Gaucher disease Type 1 expected by year end; program for FLT190 for Fabry disease progressing Completed first dose cohort for FLT190 Phase 1/2 dose-finding tr...
FRLN - Freeline Provides Executive Leadership Team Update; Company to Provide Corporate Update and Second Quarter 2021 Financial Results on Monday, August 16

LONDON, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from inherited systemic ...

FRLN - Shares of Freeline Therapeutics Holdings plc (FRLN) Fall to a New 52-Week Low

Freeline Therapeutics Holdings plc (NASDAQ:FRLN) traded at a new 52-week low today of $4.60. This new low was reached on above average trading volume as 478,000 shares traded hands, while the average 30-day volume is approximately 238,000 shares. Freeline Therapeutics Holdings plc (NASDA...

FRLN - Shares of Freeline Therapeutics Holdings plc (FRLN) Have Fallen Below Previous 52-Week Low

Freeline Therapeutics Holdings plc (NASDAQ:FRLN) traded today at a new 52-week low of $4.89. Approximately 478,000 shares have changed hands today, as compared to an average 30-day volume of 231,000 shares. There is potential upside of 19.5% for shares of Freeline Therapeutics Holdings p...
Previous 10 Next 10